GW Pharma’s marijuana-derived epilepsy drug sales continue to climb

GW Pharmaceuticals Inc. reported revenue that topped the consensus estimates Tuesday, as the company’s marijuana-derived epilepsy drug continues to grow.

GW Pharma GWPH, -3.04% shares slipped about 0.1% in the extended session.

The company reported a fourth-quarter net loss of $24.9 million, which amounts to 7 cents a share, versus a loss of $71.9 million, or 20 cents a share, in the year-ago quarter.

Revenue rose to $109.1 million from $6.6 million a year ago and $93 million in the third quarter. GW Pharma said that it sold $104.5 million of Epidiolex in the fourth quarter. Epidiolex is a U.S. Food and Drug Administration-approved drug used to treat several forms of epilepsy that is derived from cannabidiol, or CBD.

“2019 was an exceptional and transformative year for GW, led by the successful launch of Epidiolex in the U.S. and approval in Europe,” Chief Executive Justin Grover said in a statement. “We also expect 2020 to be an important year for our growing and developing product pipeline beyond Epidiolex as we build on our world leadership in cannabinoid science.”

GW Pharma said earlier this month that it had submitted an application to expand the label for Epidiolex to include the treatment of seizures associated with Tuberous Sclerosis Complex.

GW Pharma had pre-announced earnings in January, telling investors it expected fourth-quarter revenue of roughly $108 million, with $104 million arriving from sales of Epidiolex.

Analysts surveyed by FactSet had estimated earnings of 3 cents a share on revenue of $105.3 million. Sell-side analysts modeled first-quarter revenue of $110.4 million.

GW Pharma stock has fallen 22% in the past year, with the S&P 500 index SPX, -3.03% rising 15.4%.

Source: Read Full Article